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Abstract
The present article intends to provide an update of the article “Focus on prevention, diagnosis and treatment of
hypertension in children and adolescents” published in 2013 (Spagnolo et al., Ital J Pediatr 39:20, 2013) in this
journal. This revision is justified by the fact that during the last years there have been several new scientific
contributions to the problem of hypertension in pediatric age and during adolescence. Nevertheless, for what
regards some aspects of the previous article, the newly acquired information did not require substantial changes to
what was already published, both from a cultural and from a clinical point of view. We felt, however, the necessity
to rewrite and/or to extend other parts in the light of the most recent scientific publications. More specifically, we
updated and extended the chapters on the diagnosis and management of hypertension in newborns and
unweaned babies, on the use and interpretation of ambulatory blood pressure monitoring, and on the usefulness
of and indications for physical activity. Furthermore, we added an entirely new section on the role that simple
carbohydrates (fructose in particular) and uric acid may play in the pathogenesis of hypertension in pediatric age.
Background
A few years ago we published in this journal an article
on prevention, diagnosis and treatment of hypertension
in children. During the last years there have been several
new scientific contributions to the problem of hyperten-
sion in pediatric age and during adolescence. For this
reason we felt the necessity to rewrite and/or to extend
some parts of the previous article in the light of the
most recent scientific publications.
Hypertension in newborns and unweaned babies
The incidence of hypertension in healthy newborn in-
fants is considered so low that blood pressure measure-
ment is not recommended among the procedures to be
performed during the first days of life; instead, the inci-
dence appears to be higher (about 1-2 %) in newborns
hospitalized in intensive care units. Reference values are
based on surveys on a limited number of cases such as
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the American Task Force [1], or on a more numerous
population in the study by Kent et al. published in 2007
in Pediatric Nephrology [2]. A recent review [3] of 43
studies confirms that sufficient data for the definition of
normal blood pressure values in neonates are lacking,
and that there are no follow-up data allowing the defin-
ition of those blood pressure values that, due to risk of
organ damage, would require pharmacological treat-
ment. Blood pressure values seem to be inversely pro-
portional to gestational age and birth weight, increase in
full-term newborns during of the first week of life, and
increase during the first 15 days in early preterm infants
(gestational age less than 31 weeks) [4, 5] and then seem
to level off. These different behaviors are presumably
due to the late closure of the ductus arteriosus and to
the slower reduction of pulmonary resistances in pre-
term infants. In full-term babies blood pressure seems
mainly associated with weight, whereas in preterm ba-
bies it appears to be related to gestational age. The
measure of blood pressure that is generally used as a ref-
erence during the first month of life is mean blood pres-
sure, as it best represents the overall hemodynamic
situation at this stage. Mean blood pressure is obtained
by summing the diastolic and 1/3 of the systolic blood
pressure values. Among the available published surveys
[6–10], both for preterm and for full-term babies we be-
lieve that currently it is advisable to use the study by
Dionne that provides blood pressure values correspond-
ing to the 50th, 95th, and 99th percentile at 15 days of age
according to gestational age [10] (Table 1). The defin-
ition of the 99th percentile is important, because it
distinguishes patients that need closer diagnostic exam-
ination and sometimes pharmacological therapy from
those with borderline blood pressure values for whom
an accurate follow-up may be sufficient. Regarding blood
pressure progression with time in the infants, reference
values for systolic and diastolic blood pressure during
the first 12 months of life are reported in Fig. 1 [1].
The method used for measuring blood pressure is an
important factor. In newborns, when invasive recording
of blood pressure is impossible, the oscillometric
method is almost universally accepted as being reliable.
The majority of measuring errors is caused by the use of
inappropriate cuffs, a mistake that occurs in older chil-
dren as well. Whereas in children it is advised that the
width of the cuff be 40 % of the circumference of the
arm, in newborn babies it has been shown that by using
a cuff whose width equals 50 % of the arm circumfer-
ence it is possible to detect blood pressure values that
correspond with the intra-arterial ones [11]. It has also
been demonstrated that the choice of the cuff after ac-
tual measurement of the arm’s circumference is much
more accurate than the choice based on visual assessment,
even if done by expert health workers [12]. Therefore the
measurement of the arm circumference is an essential as-
pect of blood pressure assessment in neonates.
We can conclude that blood pressure measurement
shouldn’t routinely be done in healthy newborns, but we
also think that is mandatory to monitor blood pressure
in neonatal intensive care unit, particularly in subjects
submitted to mechanical ventilation, in sub-intensive
care and whenever a newborn is at high risk for hyper-
tension, due to either sickness or syndromic clues. The
potential harms caused by false diagnosis of hyperten-
sion must be kept in mind and avoided by repeated mea-
surements, performed by expert health workers.
Causes of hypertension in neonates
Neonatal hypertension is almost always secondary to an
underlying disease or to a pre-existing clinical condition
and is generally diagnosed in neonates hospitalized in
the intensive care unit. Among the risk factors associ-
ated with hypertension, catheterization of the umbilical
artery seems to have great importance and, as emerges
from several studies [13–17] frequently causes aortic or
renal thrombosis. Some prenatal factors are found to be
related to an increased incidence of neonatal hyperten-
sion, and most of all maternal hypertension (gestational
or prior to pregnancy) and the use of corticosteroids by
pregnant women [18] seem to be implicated. The main
causes of neonatal hypertension can be classified in the
following groups: renal parenchymal, renovascular, due
to compression of renal vessels or aorta (abdominal
masses, defects of closure of the abdominal wall), cardiac,
iatrogenic, malformations, endocrine, neurologic, respira-
tory (Table 2). The etiology of hypertension is quite differ-
ent for preterm compared to full-term babies: in preterms
the clearly most prevalent causes are bronchodysplasia and
iatrogenic factors. Bronchodysplasia has been identified as
Table 1 Gestational age and blood pressure values in
newborns
GA
(weeks)
50th percentile 95th percentile 99th percentile
SBP DBP MBP SBP DBP MBP SBP DBP MBP
44 88 50 63 105 68 80 110 73 85
42 85 50 62 98 65 76 102 70 81
40 80 50 60 95 65 75 100 70 80
38 77 50 59 92 65 74 97 70 79
36 72 50 57 87 65 72 92 70 77
34 70 40 50 85 55 65 90 60 70
32 68 40 49 83 55 64 88 60 69
30 65 40 48 80 55 63 85 60 68
28 60 38 45 75 50 58 80 54 63
26 55 30 38 72 50 57 77 56 63
Modified from Dionne et al. [10]
GA gestational age, SBP systolic blood pressure, DBP diastolic blood pressure,
MBP mean blood pressure
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a cause of systemic hypertension by Abman in 1984 and
this observation has been confirmed by later studies
[19–21]. The incidence of hypertension among neonates
with very low birth weight and bronchodysplasia is twice
compared to newborns without bronchodysplasia and ap-
pears to be associated with the severity of the pulmonary
disease [21]. The pathogenetic mechanisms that connect
bronchodysplasia and hypertension are not quite clear.
Possible mechanisms that are especially taken into consid-
eration are impaired neurohumoral regulation, increased
levels of catecholamines, angiotensin and antidiuretic hor-
mone, but also merely the frequent use of umbilical arter-
ial cathetherization in these patients [22]. Many drugs that
are commonly administered to preterm infants can induce
hypertension; dexamethasone and other corticosteroids
used to treat chronic pulmonary diseases, catechol-
amines (dopamine, adrenaline), xanthines (caffeine
and theophylline), curare-mimetics (pancuronium) and
mydriatic eye drops (phenylephrine). The hypertension in-
duced by these drugs may in some cases last even for a
certain time after the interruption of the drug itself. Sev-
eral studies have shown an higher incidence of systemic
hypertension in preterm infants treated for patent ductus
arteriosus; in these cases the elevated blood pressure may
be related to the possible nephrotoxic effect of indometh-
acin, to renal hypoperfusion due to diastolic theft caused
by the patent ductus, to increased stroke volume following
closure of the ductus or, finally, to thromboembolic events
[18, 20, 23] In full-term infants hypertension is most
frequently associated with renal diseases; other causes are
observed with more or less equivalent prevalence.
Newborns suffering from some malformation syndromes
(DiGeorge, CHARGE, VACTERL, Congenital Rubella,
Potter) may sometimes present hypertension as a conse-
quence of renal, cardiac or vascular malformations.
Clinical approach
Whenever an elevated blood pressure is detected, the
method of measurement should be verified and it would
be necessary, at least once, to measure the blood pres-
sure at all four extremities in order to exclude the pres-
ence of aortic coarctation. Subsequently the most
frequent causes of hypertension (Table 3) are to be ex-
cluded and it should be evaluated if the currently in-
stalled therapy involves potentially hypertensive drugs.
In infants the malformation syndromes are often charac-
terized by the vague nature of their signs and therefore
it is important to pay close attention to facies, nasal
bridge, positioning of the ears, the possible presence of a
nuchal fold and to ask for genetic counselling in case of
doubt. Careful examinations of the heart and abdomen
are crucial. Serum levels of creatinine and electrolytes
Fig. 1 Percentiles of systolic and diastolic blood pressure from birth to 12 months of age Task Force on Blood Pressure Control in Children.
Modified from Pediatrics 1987 [1]
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should be determined and a urine test should be per-
formed in order to exclude renal parenchymal disorders.
Renal vein thrombosis should be suspected in neonates
presenting haematuria, thrombocytopenia, palpable renal
mass or anuria. Ultrasonography is usually sufficient for
the diagnosis: typical findings include an enlarged kid-
ney, increased echogenicity around interlobular vessels
and loss of cortico-medullary differentiation. The direct
visualization of the thrombus in the renal vein or in the
inferior vena cava is often possible. In case of renal vein
thrombosis, the doppler ultrasound scan demonstrates
an absent flow in the renal vein.
The presence of thrombophilia may confirm the hy-
pothesis of renal vein thrombosis. Only as a second step
and if the clinical history suggests to do so, cortisol and
aldosterone levels and the thyroid function should be
assessed. Plasma renin activity is normally very high in
newborns, and consequently it is not to be assessed, un-
less a marked hypokalemia is found that may possibly be
related to a genetic anomaly in the tubular sodium man-
agement. Echo-Doppler examination of the renal vessels
is essential for excluding renal malformations and aortic
or renal intravascular thrombi. Until a few years ago,
angiography was considered the gold standard for the
diagnosis of renal artery stenosis due to fibrodysplasia,
but was difficult to carry out in newborns. The search
for less invasive diagnostic methods has recently resulted
in obtaining a very high diagnostic sensitivity and speci-
ficity by combining color-Doppler technique to nuclear
Table 2 Causes of neonatal hypertension
Renovascular
Renal artery stenosis
Renal artery thrombosis
Renal venous thrombosis
Renal parenchymal disease/obstructive uropathy
Polycystic kidney disease
Acute tubular necrosis
Nephrocalcinosis
Severe vesicoureteral reflux
Stenosis of ureteropelvic junction
Posterior urethral valve
Ureterocele
Other causes of acute and chronic renal insufficiency
Cardiac
Aortic coarctation
Aortic arch reconstruction
Patent ductus arteriosus
Endocrine
Congenital adrenal hyperplasia (17 alpha or 11 beta hydroxylase deficiency)
Hyperthyroidism
Hyperaldosteronism
Hypercalcemia
Neurologic
Intracranial hypertension
Seizures
Intraventricular hemorrhage
Abstinence syndrome from opioid withdrawal
Pain
Neoplasia
Neuroblastoma
Wilms tumor
Pheochromocytoma
Closure of abdominal wall defect
Gastroschisis
Giant omphalocele
Iatrogenic
Dexamethasone and other corticosteroids
Methylxanthines (caffeine, theophylline)
Vasoactive amines (dopamine, adrenaline)
Bronchodilators
Phenylephrine
Parenteral nutrition (volume overload, sodium, calcium)
Extracorporeal respiratory assistance
Table 2 Causes of neonatal hypertension (Continued)
Malformation syndromes
DiGeorge
Potter
Congenital Rubella
CHARGE
VACTERL
Table 3 Guiding criteria for the diagnosis of neonatal
hypertension
The most frequent prenatal causes of neonatal hypertension are:
1. repeated use of steroids by mother
2. maternal diabetes mellitus
3. maternal hypertension
The most frequent postnatal causes of neonatal hypertensione are:
1. thromboembolism associated with the placement of an umbilical
cathether, involving an acute risk presumably due to endothelial damage
and a chronic risk related to the time the cathether stays in place
2. renal parenchymal disease, both congenital (eg. polycystic kidney
disease) and acquired
3. bronchopulmonary dysplasia (CLD)
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magnetic resonance or to a computed tomography scan
with contrast. This latter method provides better defin-
ition, even though at a high level of toxicity [24, 25].
Treatment
A wide variety of drugs is being used in the treatment of
hypertension in neonates, but the indications provided
by literature are exclusively based on isolated surveys or
on expert’s opinions and no controlled studies on effi-
cacy an safety are available. For these reasons the use of
antihypertensive agents in this age range is generally not
approved by the regulatory authorities (AIFA, EMEA,
FDA) and should be considered off-label. There is not
even a unanimous consensus on which blood pressure
values would benefit from treatment, as it is not well
known what are the harmful effects of persistently high
blood pressure levels at this age. In any case it is appro-
priate to consider pharmacological treatment when
blood pressure repeatedly exceed the 99th percentile. Be-
fore starting therapy the possibility to remove the cause
of hypertension should be examined (iatrogenic causes
or conditions that can be treated surgically, such as co-
arctation of the aorta, some neoplasias or certain uro-
logic diseases). Instead, when it is necessary to resort to
medical treatment it is advisable to use intravenous ad-
ministration in all the emergency situations in which it
is beneficial to allow quick dose changes according to
the blood pressure response; oral administration is indi-
cated in less urgent cases or as long-term treatment after
having succeeded in controlling the hypertension by
intravenous therapy. Among the different classes of anti-
hypertensive drugs, ACE-inhibitors are the most fre-
quently used in newborns, especially when renal diseases
are present [26]. However, some authors [27] have rec-
ommended not to use ACE-inhibitors in preterm neo-
nates because of their possible negative effects of the
development of the kidney. Moreover, in these particular
children the reaction to these drugs is rather unpredict-
able and there is a certain risk of causing profound
hypotension with possible renal failure and severe
neurological consequences. In particular, in the case of
captopril in preterm neonates it is advised to use initial
doses that are much lower than those used in full-term
babies [28]. Diuretics (hydrochlorothiazide, furosemide,
spironolactone) are also widely used in newborns and
should be the first choice treatment in case of broncho-
dysplasia, as they show positive effects on pulmonary
mechanics. In this kind of patients, and generally in all
preterm neonates with cardiorespiratory instability, beta-
blockers should be used with much caution, due to the
risk of episodes of severe apnea and bradycardia [29].
Arteriolar vasodilators (especially hydralazine) and cal-
cium antagonists are found to be most frequently used
in some America case records, both in acute situations
and as long-term treatment [20, 30]. Table 4 summarizes
the oral and intravenous drugs that can be used, indicat-
ing doses, frequency and mode of administration, and
information on which precautions to take and on pos-
sible side effects.
Organ damage
Hypertension is the main cause of myocardial hyper-
trophy with consequent fibrosis and dilatation; in adults
such conditions are associated with cardiac and non-
cardiac morbidity and untimely mortality [31–33] Anti-
hypertensive therapy causes a reduction in blood
pressure and cardiac mass. However, it has never been
demonstrated that normalization of blood pressure and
cardiac mass brings cardiovascular risk to the same level
of subjects who were never hypertensive; what is more,
it seems that hypertensive patients, even though treated
correctly and achieving efficient reduction of blood pres-
sure levels, still remain at increased risk compared to
normotensives. The few available studies on this subject
in pediatric age seem to support this theory [34, 35].
Thus it is important, even in young children, to prevent
hypertension or at least prevent left ventricular hyper-
trophy. Cardiac hypertrophy can be easily assessed by
echocardiography that, by measuring the wall thick-
nesses and dimension of the chambers, allows to deter-
mine cardiac mass with an appropriate formula which
provides a good correspondence with necropsy left ven-
tricular mass [36]. Cardiac mass as expressed in grams is
indexed according to weight and/or height of the sub-
ject. Scientific knowledge on hypertension-induced
organ damage in childhood is scarce, but it is known
that also children react to increases in blood pressure
with increases in cardiac mass, and thus presumably suf-
fering all the same consequences and risks as those de-
scribed for adults [37]. Information on neonates is even
more scanty. The heart of newborn infants still has the
capacity to increase the number of myocytes (hyperpla-
sia). Within one year of age this capacity gradually di-
minishes. As the rate of growth of cardiac mass is
inversely proportional to age, in a short time lapse se-
vere hypertension can induce a considerable hypertrophy
with a consequent rise in the associated risk of death in
newborns and unweaned babies [38]. Even if shown in a
limited number of subjects, an increase in mass of more
than 100 % compared to baseline values may be associ-
ated with an increased mortality [39]. In conclusion, a
rapid development of ventricular hypertrophy represents
a negative prognostic factor of survival and requires a
timely and efficient treatment, especially when considering
that blood pressure reduction in this age range seems to
bring about an correspondingly rapid regression of the
hypertrophy. The risks associated to increased cardiac mass
and the age-related high rate of hypertrophy development,
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make careful cardiologic follow-up of cases of severe hyper-
tension in infants and unweaned babies quite crucial. Arter-
ial stiffness evaluated by pulse wave velocity and
ultrasonography measurement of intimal media thickness
are important independent predictors of cardiovascular
events in adults and indicators of cardiovascular risk in
Table 4 Drugs useful in the treatment of neonatal hypertension
Drug Class Dose Route Comments
Intravenous agentsa:
Diazoxide Vasodilator (arteriolar) 2–5 mg/kg/dose Rapid bolus injection Slow injection is ineffective.
Duration unpredictable.
May cause rapid hypotension.
Enalaprilat ACE-inhibitor 15 ± 5 μg/kg/dose; repeat
after 8–24 h
Injection over 5–10 min May cause prolonged hypotension
and acute renal insufficiency.
Esmolol β-blocker 100–300 μg/kg/min IV infusion Very short-acting. Constant infusion
necessary.
Hydralazine Vasodilator (arteriolar) Bolus: 0.15–0.6 mg/kg/dose
every 4 h.
Drip: 0.75–5.0 μg/kg/min
IV bolus or infusion Frequently causes tachycardia.
Labetalol α- and β-blocker 0.20–1.0 mg/kg/dose
0.25–3.0 mg/kg/h
IV bolus or constant infusion Heart failure and BPD are relative
contraindications.
Nicardipine Calcium antagonist 1–3 μg/kg/min Constant infusion May cause reflex tachycardia.
Sodium nitroprusside Vasodilator (arteriolar
and venous)
0.5–10 μg/kg/min Constant infusion In case of prolonged therapy (>72 h)
or renal failure thiocyanate toxicity
may occur.
Drug Class Dose Interval Comments
Oral agentsa
Captopril ACE-inhibitor 0.01–0.5 mg/kg TID Monitor serum creatinine and
potassium.
Clonidine Central α-agonist 0.05–0.1 mg/kg? BID-TID Side effects: sedation, dryness of the
mucosa. Abrupt interruption may
cause rebound hypertension.
Hydralazine Vasodilator (arteriolar) 0.25–1.0 mg/kg (max 7.5
mg/kg per day)
TID-QID Frequent side effects: fluid retention
and tachycardia. Lupus-like syndrome
may occur in slow acetylators.
Isradipine Calcium antagonist 0.05–0.15 mg/kg QID Useful for both chronic and acute
hypertension.
Amlodipine Calcium antagonist 0.1-0.3 mg/kg BID Causes sudden hypertension less
frequently than isradipine.
Nifedipine Calcium antagonist 0,25–0,5 mg/kg
Max. dose: 1–2 mg/kg per day
Repeat every 4–6 h Hypotensive response poorly
predictable.
Minoxidil Vasodilator (arteriolar) 0.1–0.2 mg/kg BID-TID The most potent oral vasodilator.
Hypertrichosis in case of prolonged
use.
Propranolol β-blocker 0.5–1.0 mg/kg TID Maximum dose to be defined
according to heart rate (up to 8–
10 mg/kg if no bradycardia). Not to
be used in infants with BPD.
Atenolol β-blocker 0.8–1 mg/kg
Max. dose 2 mg/kg per day
QD
Labetalol α- and β-blocker 1.0 mg/kg BID-TID Monitor heart rate. Not to be used in
infants with BPD.
Spironolactone Aldosterone antagonist 0.5–1.5 mg/kg BID Potassium-sparing. Check serum
electrolytes. May take several days to
reach maximum effectiveness.
Hydrochlorothiazide Thiazide diuretic 1–3 mg/kg QID Check serum electrolytes.
Chlorothiazide Thiazide diuretic 5–15 mg/kg BID Check serum electrolytes.
amodified from Flynn, [6]
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childhood [40, 41]. Both pulse wave velocity and intimal
media thickness have been shown to be reliably ascer-
tained in newborns with good reproducibility, but normal
reference values are still lacking. So it is difficult to distin-
guish between the normal progressive structural changes
in the arterial wall in this age group and differences due to
the systemic blood pressure [42, 43]. Furthermore recent
data show significantly increased intimal media thickness
and pulse wave velocity values during infancy in growth
restricted foetuses, not always related to a significant trend
because of high blood pressure values, supporting that
possibility of fetal cardiovascular programming leading
later in life on to hypertension [44].
Prevention of primary hypertension: programming
In recent years it has been established that primary
hypertension, besides being controlled by an important
genetic component, is influenced by environmental stim-
uli according to the concept of programming; i.e. the
process by which a stimulus or a lesion to an organism
during a critical period of its development determines
long-lasting or even permanent effects. While the dur-
ation of the stimulus is certainly important, the period
in life in which it occurs is even more critical. If com-
mon stimuli affecting blood pressure such as stress, diet,
drugs, are present during intrauterine life or during the
first year of life, they may alter the programming and de-
termine permanent changes in blood pressure [45].
There is some debate about the pathogenetic mechan-
ism; the initial hypothesis that still stands is the so-
called unifying pathway by Woods [46], according to
which environmental and placental factors, such as ma-
ternal protein restriction, alterations in the placental or
uterine circulation, or placental insufficiency, which all
determine low birth weight, may cause hypertension in
adulthood due to activation of the renin-angiotensin sys-
tem as a consequence of a low number of nephrons.
Furthermore, according to the hypothesis developed by
Barker [47], scarce intrauterine growth would cause a
deterioration in insulin resistance, and in turn, elevated
levels of insulin have been associated with increased
blood pressure also in children [48]. Several studies re-
port that adolescents and adults who were born prema-
turely have a mean blood pressure that is higher than
the one observed in full-term peers or show an increased
pressure load (number of ambulatory blood pressure
measurements beyond normal values), both indicative of
a predisposition for the development of hypertension
[49–51]. More recent data suggest that even children of
premature parents, though they themselves were born
after a full-term delivery, present modest abnormalities
in their cardiovascular disposition (higher heart rate or
elevated blood pressure values, yet remaining within the
normal range). These observations seem to confirm that
changes induced by environmental stimuli can be inher-
ited by the following generations [52]. Another import-
ant factor is represented by the type of nutrition during
the first year of life. One of the beneficial effects of
breastfeeding is the reduction of blood pressure at later
age, but also mixed feeding seems to be effective. In fact,
in 2001 Singhal et al. reported in Lancet [53] that dia-
stolic blood pressure at 14–16 years of age is inversely
proportional to the percentage of mother’s milk in the
diet during the first months of life; the more mother’s
milk had been consumed, the lower was diastolic blood
pressure. It is known that potassium inhibits the renin-
angiotensin system. The high content of potassium in
vegetables, but also potassium in formula milk, the
quantity of which may vary a lot according to the type of
milk, may affect blood pressure values [54, 55]. All these
studies emphasize the importance of very early prevent-
ive strategies, starting as early as in pregnancy, involving
lifestyle and diet interventions in order to maintain a
healthy condition in the long term.
Ambulatory blood pressure monitoring in pediatric
hypertension: how and when to use it
In 2008 the first recommendations were published for
the use and interpretation of 24-h ambulatory blood
pressure monitoring (ABPM) in children and adoles-
cents [56]. As specified in the introduction of that publi-
cation, these “recommendations” were meant to be
considered experts’ opinion, because the limited number
of clinical data did not allow to define them as “guide-
lines”. The document, though emphasizing the import-
ance of ABPM in the assessment of blood pressure
values in children and adolescents, pointed out some
critical points concerning its use. In particular, the lack
of solid reference values for normal subjects was under-
lined; the tables reported in the recommendations had
been derived from the only study that had provided suf-
ficient data for the creation of specific nomograms, sub-
divided according to gender and age, or gender and
height [57]. The study population (949 subjects) was
composed of children of a single ethnicity (Caucasian)
within an age range of 5–16 years. The authors con-
firmed the fact that diagnosis of hypertension in
pediatric age should be based on repeated blood pres-
sure measurements performed in the doctor’s office as
indicated by the Fourth Report on the Diagnosis, Evalu-
ation and Treatment of High Blood Pressure in Children
and Adolescents [58], but they also suggested useful cri-
teria for the classification of blood pressure values ob-
tained by ABPM. Besides referring to the percentiles
proposed by Wühl, the recommendations added the
concept of blood pressure load, to be intended as the
percentage of measurements revealing pressure levels
above the 95th percentile [59]. A blood pressure load
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exceeding 25 % is considered elevated. When the mea-
sured percentage of pathological blood pressure values is
above 50 % this outcome is an indication of severe hyper-
tension (at risk of organ damage) [60]. In short, the docu-
ment advised the use of ABPM for the confirmation of
hypertension (identification of white coat hypertension or
masked hypertension), for the assessment of blood pres-
sure variability (presence of physiological nocturnal fall,
dipping) and of blood pressure load, and to verify the effi-
cacy of therapy in treated subjects, especially in secondary
forms of hypertension. Six years later an update of these
recommendations was published [61]. In this update the
authors implement the previous recommendations with
new data emerging from the recent literature and propose
a revision of the classification scheme that was published
in the 2008 document, more accurately defining children
with prehypertension (Table 5); furthermore they intro-
duce the concept of diastolic hypertension. In the intro-
duction it is again declared that this document should be
considered an experts’ opinion, even though supported by
more important clinical evidence compared to the preced-
ing version. The blood pressure nomograms advised for
the interpretation of ABPM values remain identical com-
pared to the 2008 recommendations, as actually no new
studies on larger and differentiated populations to define
new reference values had been performed in the mean-
time. Tables 6, 7, 8 and 9 summarize ambulatory systolic
and diastolic blood pressure reference values (mean
values, daytime and nighttime, 90th and 95th percentiles)
according to gender and height and to gender and age.
The authors emphasize the necessity to more precisely
identify the relationship between different ABPM patterns
and the presence of organ damage. The new document
more clearly explains a number of crucial points for the
correct performance of ABPM in children; Our aim is to
summarize and comment these points.
ABPM and organ damage
Several studies reported a correlation between blood pres-
sure values observed in pediatric age and the presence of
organ damage in adulthood, and in particular the presence
of left ventricular hypertrophy, carotid intima-media
thickening and increase in arterial stiffness [62–64].
ABPM appears to be more effective compared to office
blood pressure measurements in identifying children at in-
creased risk of developing organ damage. A study by Sorof
[65] clearly shows diagnosis of hypertension in children
on the basis of ABPM data is more significantly related to
the prevalence of left ventricular hypertrophy than hyper-
tension diagnosed by office blood pressure measurements.
In a review of the National High Blood Pressure Education
Program Working Group the risk of developing left ven-
tricular hypertrophy, in terms of odds ratio, was 7.2 in
hypertension diagnosed by ABPM vs 4.1 in hypertension
based on office measurements [66]. In another study, the
blood pressure values obtained by ABPM were shown to
be superior in predicting LVH than both office and home
(self-measurement) blood pressure values [67]. Fur-
thermore, in several studies blood pressure values re-
corded by ABPM were associated with another well-
Table 5 Scheme for the classification of systolic and diastolic blood pressure values obtained by 24-h blood pressure monitoring in
children
Classification Office SBP/DBP a 24-h ambulatory SBP/DBP b SBP or DBP load (%) b
Normal blood pressure <90th percentile <95th percentile <25
White coat hypertension ≥95th percentile <95th percentile <25
Prehypertension ≥90th percentile <95th percentile ≥25
Masked hypertension <95th percentile >95th percentile ≥25
Hypertension >95th percentile >95th percentile 25–50
Severe hypertension >95th percentile >95th percentile >50
Dipping subjects: mean nocturnal values at least 10 % lower than diurnal values
a The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents, [58]
b Modified from Flynn JT et al. [61]
Table 6 Normal values for ambulatory BP (mmHg) for girls by
height
Height
(cm)
24 h Day Night
90th p 95th p 90th p 95th p 90th p 95th p
120 112/71 114/72 118/80 120/82 103/63 106/65
125 113/71 116/73 119/80 121/82 104/63 107/66
130 114/72 117/72 120/80 122/82 106/63 108/66
135 115/72 118/74 120/80 123/82 107/63 109/66
140 116/73 119/75 121/80 124/82 108/63 110/66
145 117/73 120/75 122/80 125/82 109/63 112/66
150 119/74 121/76 124/80 127/82 110/63 113/66
155 120/74 123/76 125/80 128/82 111/63 114/66
160 121/74 123/76 126/80 129/82 111/63 114/66
165 122/74 124/76 127/80 130/82 112/63 114/66
170 123/74 125/76 128/80 131/82 112/67 115/71
175 124/75 126/76 129/81 131/82 113/63 115/66
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known cardiovascular risk factor, namely carotid intima-
media thickness [68, 69]. Litwin et al. [70] documented, in
72 children with essential hypertension, a correlation be-
tween intima-media thickness in the carotid and superficial
femoral arteries and 24-h systolic blood pressure values. Fi-
nally, others authors documented a correlation between
ABPM values and some parameters of artery distensibility
and stiffness or with indices of endothelial dysfunction as
flow-mediated or nitroglycerin-mediated dilation [71, 72].
Indications for the use of ABPM
Data provided by ABPM consist of the mean of systolic
and diastolic blood pressure values recorded during 24 h
and, separately, during waking hours (daytime mean)
and during sleep (nighttime mean). The recording of
nighttime blood pressure allows the determination of
the presence of the physiological fall in blood pressure
during sleep (dipping), which should be at least 10 % of
the diurnal blood pressure mean. The absence of a
nighttime fall in blood pressure and the presence of
isolated nocturnal hypertension have been shown to be im-
portant prognostic factors in several forms of secondary
hypertension, especially those due to renal damage
[73–76]. Another important concept to use in the in-
terpretation of a 24-h recording is pressure load. A
correct definition of all these parameters requires an
adequate identification of the actual periods of sleep
and wakefulness in the patient.
ABPM and clinical condition
White coat hypertension The American recommenda-
tions suggest to perform ABPM in children with ele-
vated office blood pressure values in whom an excess
reactivity to the measurements (white coat hypertension)
is suspected, in order to confirm such possible diagnosis.
However, as initial organ damage may already be present
in subjects with white coat hypertension [77–80] in the
last recommendations it is suggested to consider white
coat hypertensives only those subjects with borderline or
moderately elevated office blood pressure values, be-
cause subjects with even higher blood pressure could be
real hypertensives, as demonstrated by Sorof [81]. An in-
crease in left ventricular mass has in fact been demon-
strated in children with white coat hypertension [77]
Table 8 Normal values for ambulatory BP (mmHg) for girls by
age
Age (years) 24 h Day Night
90th p 95th p 90th p 90th p 95th p
5 112/72 115/74 118/80 121/82 105/66 109/69
6 114/72 116/74 120/80 122/82 106/65 110/68
7 115/72 118/74 121/80 123/82 107/65 111/67
8 116/72 119/74 122/80 124/82 108/64 112/67
9 117/73 120/74 122/80 125/82 109/64 112/67
10 118/73 121/75 123/79 126/81 110/64 113/66
11 119/73 122/75 124/79 127/81 110/63 114/66
12 120/74 123/76 125/80 128/82 110/63 114/66
13 121/74 124/76 126/80 129/82 111/63 114/66
14 122/74 125/76 127/80 130/82 111/63 114/65
15 123/75 125/77 128/80 130/82 111/63 114/65
16 123/75 126/77 129/82 131/82 111/63 114/65
Table 9 Normal values for ambulatory BP (mmHg) for boys by age
Age (years) 24 h Day Night
90th p 95th p 90th p 90th p 95th p
5 114/72 116/74 120/79 123/81 103/62 106/65
6 115/73 118/75 121/79 124/81 105/63 108/66
7 116/73 119/75 122/80 125/82 106/64 110/67
8 117/73 120/75 122/80 125/82 108/64 111/67
9 118/73 121/75 123/80 126/82 109/64 112/67
10 119/73 123/75 124/80 127/82 110/64 113/67
11 121/74 125/76 126/80 129/82 111/64 115/67
12 124/74 127/76 128/80 132/82 113/64 116/67
13 126/74 130/76 131/80 135/82 115/64 119/67
14 129/75 133/77 134/80 138/82 118/64 121/67
15 132/75 136/77 137/81 141/83 120/64 123/66
16 135/76 138/78 140/81 144/84 123/64 126/66
ABPM: 24 h ambulatory blood pressure monitoring
Modified from Flynn JT et al. [61]
Table 7 Normal values for ambulatory BP (mmHg) for boys by
height
Height
(cm)
24 h Day Night
90th p 95th p 90th p 90th p 95th p
120 114/74 117/77 122/80 125/82 103/61 106/63
125 115/74 118/77 122/80 125/82 105/61 108/61
130 116/74 119/77 122/80 122/82 106/62 110/64
135 117/74 120/77 123/80 126/82 108/63 111/65
140 118/75 121/77 123/80 126/82 109/63 113/65
145 120/75 123/77 124/79 127/81 111/64 114/66
150 121/75 124/77 125/79 128/81 112/64 116/66
155 123/75 126/77 127/79 130/81 113/64 117/66
160 124/75 127/77 129/79 133/81 114/64 118/66
165 126/75 129/78 132/80 135/82 116/64 119/66
170 128/75 131/78 134/80 138/82 117/64 121/66
175 130/75 133/78 136/80 140/83 119/64 122/66
180 131/76 134/78 138/81 142/83 120/64 124/66
185 133/76 136/78 140/81 144/84 122/64 125/66
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and it has been shown that also subjects who occasion-
ally have blood pressure values above the 95th percentile
(transitory hypertensives) may be at increased risk of
presenting left ventricular hypertrophy [34]. For these
reasons we believe that when normal ABPM values are
observed in the presence of elevated office blood pres-
sure values, these children should not be excluded from
careful follow-up.
Masked hypertension Children who present normal of-
fice, but elevated ABPM blood pressure values are de-
fined as having masked hypertension. Some studies
suggest that masked hypertension in children is associ-
ated with early organ damage and that it may be a pre-
cursor of sustained forms of hypertension [82, 83]. For
this reason the American recommendations consider it
appropriate to perform ABPM in subjects in whom this
form of hypertension is suspected. Unfortunately the
real prevalence of masked hypertension in children is
not known and it would take many ABPM recordings in
large non-selected populations to define it. The problem
of the identification of children with white coat hyper-
tension or masked hypertension is even more compli-
cated by the recently published observations of Salice et
al. [84]. In this important study it is shown how, in a
high number of children, the correspondence between
office and ABPM blood pressure values changes accord-
ing to age and clinical conditions of the subjects (Fig. 2).
While children in the low age range and normotensive
children had higher systolic and diastolic blood pressure
at ABPM than in the office, both older and hypertensive
subjects showed lower ABPM values compared to the
ones measured in the doctor’s office. These data suggest
the need to pay particular attention in the diagnosis of
white coat hypertension and masked hypertension.
Prehypertension The term prehypertension used in this
context should not be confused with the one that was
used in the past to define those subjects presenting of-
fice blood pressure values above the 90th but below the
95th percentile and that was substituted in the most re-
cent recommendations by the term “high-normal blood
pressure”. In the present document prehypertension is
defined (Table 5) as high-normal office blood pressure
values, 24-h mean ABPM values below the 95th percentile
and a blood pressure load of 25 % of the measurements or
higher. It should be noted that in the guidelines for adults
the concept of diagnosis of prehypertension by ABPM
Fig. 2 Differences between office and ambulatory blood pressure in children and adolescents Office blood pressure-ambulatory blood pressure
differences in various subgroups of children (systolic values at left, diastolic values at right). a and b Groups defined by tertiles of age. Blue: low
age tertile (4–10 years); red: medium age tertile (10–14 years); green: high-age tertile (14–18 years). c and d Groups defined by blood pressure
status. Blue: normotensive patients (normal blood pressure in absence of treatment); red: treated hypertensive patients; green: untreated
hypertensive patients. Numbers of patients in each subgroup are indicated in Table 1. The histograms represent means of the various types of
differences listed at the bottom and bars represent _ SDs. Δ mmHg, differences in mmHg; 24-h ABP, 24-h mean of ambulatory blood pressure;
dt-ABP, mean of daytime ambulatory blood pressure; nt-ABP, mean of night-time ambulatory blood pressure; OBP, office blood pressure. From
Salice P. et al. [79] (permission required)
Strambi et al. Italian Journal of Pediatrics  (2016) 42:69 Page 10 of 22
does not exist, as in adults the assessment of pressure load
is not used; in children however, this parameter is essential
for the definition of prehypertension.
Diastolic hypertension Another important new devel-
opment in the 2014 recommendations is the introduc-
tion of diastolic blood pressure values for the diagnosis
of hypertension. In the document of 2008 the diagnosis
was based exclusively on systolic blood pressure. The
diagnostic use of ABPM-derived diastolic blood pressure
values can be important especially in children with sec-
ondary hypertension, in whom ABPM may reveal dia-
stolic hypertension [85], whereas in children with
primary hypertension ABPM more frequently indicates
systolic hypertension [86, 87].
Technical problems regarding the correct use of
Ambulatory Blood Pressure Monitoring in children
Nurse training is of fundamental importance for obtain-
ing a competent and attentive staff, capable of correctly
performing the technical part of the blood pressure mea-
surements and using the available instruments in the ap-
propriate manner. It is also essential that the nurse be
instructed on how to establish a relationship with the
children’s families in order to gain their full collabor-
ation. The nurses should inform the parents on the way
the examination will take place, teach them how to fill
in the blood pressure diary, how to reassure the children
and how to prepare them about the physical disturbance
they might perceive during the blood pressure measure-
ment. The choice of the cuff is also a crucial aspect. The
operator should measure the circumference of the child’s
arm on the central part and choose the appropriate cuff
size. The width of the cuff should be ≥ 40 % of the arm
circumference at a point midway between the acromion
and the olecranon. Cuffs that are too small overestimate
to an important degree, whereas large cuffs slightly
underestimate blood pressure values; for this reason it is
advisable to choose the larger cuff in case of doubt. The
suggested frequency of the measurements is 3–4 per
hour during daytime and 2–3 per hour during the night.
At data analysis the first measurements after positioning
of the cuff should be eliminated, anomalous data (out-
liers) should not be taken into consideration and all data
lying outside the following intervals should be discarded
(preferably directly by the reading software, or after-
wards by the operator):
Once the 24-h systo-diastolic blood pressure tracing has
been obtained, the data should be interpreted using the
appropriate pediatric nomograms (Tables 6, 7, 8 and 9)
and bearing in mind the technical aspects reported above.
Conclusions
In pediatric age ABPM should not be used “routinely”.
This test, can be extreme usefulness if used by skilled
operators and if justified by specific questions (suspicion
of white coat hypertension or masked hypertension,
need for monitoring the effectiveness of a therapy, evalu-
ation of the presence or absence of nocturnal dipping).
The use of ABPM is particularly helpful in children aged
more than 10 years. In younger children, who often do
not tolerate the examination, ABPM should be used in
targeted cases and bearing in mind that, in this age
group, office blood pressure values are lower than those
found with ABPM, and that this phenomenon tends to
attenuate over the years. A future goal regarding ABPM
in children will be to obtain more reference data for dif-
ferent age ranges and different ethnicities. It is also im-
portant to perform studies that assess the association
between ambulatory blood pressure values and organ
damage, not only by considering mean values, but also
by examining anomalies regarding pressure load and the
absence of physiological nocturnal dipping. Finally, it
would be extremely useful to carry out prospective stud-
ies that could verify if normalization of 24-h blood pres-
sure values is or is not accompanied by a regression of
pre-existing organ damage.
Hypertension and physical activity: about prevention,
therapy and certifications
Introduction
Physical activity, be it playful and recreational or
structured in organized sports, represents a fundamen-
tal cornerstone in the prevention and treatment of
hypertension in pediatric age. This consideration, even
though shared by all pediatricians and supported by
broad evidence, is generally taken for granted and only
briefly mentioned in the recommendations of the sci-
entific societies dedicated to this subject. On the con-
trary, in the present update we dedicate a section to
physical activity that is adequate and moreover propor-
tional to our conviction that it is a primary and irre-
placeable instrument in the prevention and treatment
of hypertension in view of the well-known effects
physical activity has on the pathogenetic mechanisms
of hypertension. Furthermore, we will shortly deal with
the legal aspects of the certifications for sports prac-
tice and the (few) contraindications for physical activ-
ity to be taken into consideration in children and
adolescents with hypertension.
Systolic blood pressure < 60 or > 220 mm Hg
Diastolic blood pressure < 35 or > 120 mm Hg
Heart rate < 40 or > 180 beats per minute
Pulse pressure < 40 or > 120 mm Hg
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Prevention of hypertension and its risk factors by physical
activity
The prevention of primary hypertension in children and
adolescents is based on an intervention strategy on
modifiable risk factors. Among these, the ones with the
greatest impact are: overweight, diet, salt intake, seden-
tary behavior, bad sleep quality and cigarette smoking
(also passive). Physical exercise may exert a possible ef-
fect on: overweight, sodium balance and bad quality of
sleep, thus acting indirectly on the metabolic mecha-
nisms involved in the development and maintenance of
pressure increase, such as deposition and distribution of
the fat mass, insulin resistance, activation of the sympa-
thetic nervous system, sodium homeostasis, renin-
angiotensin system, regulation of vascular function.
Obesity Obesity is the main risk factor for hypertension
in children and adolescents. A recent meta-analysis ana-
lyzed the effects of childhood obesity prevention programs
on hypertension [88]. The most effective interventions,
excluding the ones aiming at children who were already
overweight or obese, were shown to be those combining
dietary interventions with physical activity. The mean re-
duction in blood pressure obtained after 6–12 months
with the combination of the two strategies was 1.64 mmHg
for systolic and 1.44 mmHg for diastolic blood pressure.
When intervening solely on diet or physical activity the re-
sults were shown to be less successful. For that matter,
even if apparently quite modest, a reduction of blood
pressure of 2 mmHg reduces the risk of hypertension in
adulthood by up to 10 % [89]. Another meta-analysis ex-
amined nine randomized controlled trials in order to
analyze the effect of physical exercise on blood pressure at
rest in obese children [90]. The results revealed that pro-
grams comprising three exercise sessions a week, each
lasting more than 60 min, induced a reduction in systolic
blood pressure between −0.58 and −0.82 mmHg. Only if
the frequency of exercise sessions was higher than three
times a week it was possible to observe a reduction in dia-
stolic blood pressure as well.
Sodium On the average sodium intake in children and
adolescents exceeds the recommended quantities [91].
Physical activity practiced on a regular basis induces so-
dium loss through sweating, thus favoring the achieve-
ment and/or maintenance the equilibrium of the sodium
balance [92]. If the level of exercise is intensified, sweat-
ing and consequently sodium loss increases. The recom-
mendation for practice of physical activity in children at
the Centers for Disease Control and Prevention USA
indicates at least 60 min daily of moderate or intense
activity, with at least three sessions of vigorous activity a
week [93]. The many different personal and environmen-
tal factors influencing the amount of sweat produced
make it difficult to quantify the relative impact of sodium
loss by sweating due to physical activity on the overall ef-
fect of physical exercise on blood pressure.
Sleep Duration of sleep is inversely correlated to cardio-
metabolic risk, obesity and levels of physical activity in
children [94, 95]. Children that sleep more than 9 h a
night present a more intense physical activity level and
are leaner than children that sleep less. However, it is
not known if it is the higher level of motor activity (dur-
ation and/or intensity) that causes an increase in dur-
ation of sleep or vice versa [90]. Also the regularity of
sleep duration during weekdays and the weekend is re-
lated to a higher level of physical activity [96]. The
amount of time spent watching TV or playing video-
games is found to be associated with a shorter duration
of sleep [97].
Physical activity in the treatment of children and
adolescents with hypertension
The benefits of physical activity for the treatment of
hypertension have been well documented for what
regards hypertensive adults, both with and without obes-
ity [98, 99]. On the contrary evidence is less strong in
pediatric age, in which the majority of meta-analyses
and systematic reviews focus on the effectiveness of
physical activity on blood pressure values in obese chil-
dren and adolescents, as obesity represents the most fre-
quent cause of hypertension in this age range. The
mechanisms by which physical activity may affect blood
pressure in obese children and adolescents are not yet
well known. It is hypothesized that physical exercise, i.e.,
physical activity performed in a structured manner ac-
cording to precise criteria regarding type, duration, in-
tensity and frequency, acts on various mechanisms
involved in the onset of hypertension, determining a re-
duction in insulin resistance and beneficial adaptation of
the cardiovascular system (reduction in sympathetic
tone, reduction in arterial stiffness, reduction in endo-
thelial dysfunction) [100]. Furthermore, reduction in
body mass index (BMI), due to the negative caloric
balance achieved when physical activity is associated
with a diet, can cause a reduction in blood pressure of
8–12 mmHg [101]. Some observational studies demon-
strated a significant relationship between active lifestyle,
aerobic fitness and levels of blood pressure [102]. There-
fore, lifestyle changes by increasing physical activity and
reducing sedentary behavior represent the first interven-
tion strategy in pediatric hypertension (in combination
with diet, reduction of stress factors, and avoidance of
smoke and alcohol) in patients with high-normal blood
pressure or with stage 1 hypertension [103]; at the same
time, such interventions represent a complementary and ir-
replaceable therapy in those cases in which pharmacological
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treatment is needed. In order to achieve the highest prob-
ability of success, the whole family should participate in
changing the dysfunctional behavior. For what concerns the
type, intensity and duration of physical exercise to be ad-
vised in the treatment of pediatric hypertension, experi-
mental studies have shown a greater efficacy of aerobic
exercise (systolic blood pressure −1.39 mmHg; diastolic
blood pressure −0.39 mmHg) compared to muscular
strength training (systolic blood pressure −0.61 mmHg; dia-
stolic blood pressure −0.51 mmHg) [90]. The training pro-
grams based on three weekly sessions lasting more than
60 min each, were found to be more effective on systolic
blood pressure, while programs with more than three ses-
sions per week had a greater impact on diastolic blood
pressure. Even though the effect on blood pressure values
may seem quite modest, it has been hypothesized that the
reduction of at little as 1 mmHg in childhood may have an
impact on the blood pressure in adult age and on future
cardiovascular events, in view of the long cumulative period
of exposure [104]. A meta-analysis of studies in adults has
shown that a reduction of blood pressure by 2 mmHg can
reduce cardiovascular event risk by 12 % [105]. Therefore,
on the basis of scientific evidence, it is recommended to
practice physical activity for at least 5 days a week, lasting
30–60 min at moderate to vigorous intensity [106] (moder-
ate physical activity: reaching 55–75 % of maximum heart
rate; vigorous physical activity: reaching 65–85 % of max-
imum heart rate). The physical activity can be performed
both as a non-organized activity and as a physical exercise
or sport. In case a condition of elevated blood pressure is
diagnosed in children that already participate in one or
more physical activities, it may be necessary to increase the
frequency and/or intensity. Aerobic activities are to be pre-
ferred (walking, running, cycling, swimming, rowing) over
static forms of exercise. Moreover, considering the negative
and independent effect of sedentary behavior on cardio-
metabolic health, children and adolescents should be edu-
cated to monitor the time spent in sedentary activities (TV,
videogames, computer), aiming at gradually reducing the
time dedicated to these activities to less than 2 h a day
[107]. Significant effects of exercise have been shown after
3–6 months from the start of the training program [108],
but this should continue in time in order to obtain a more
lasting effect on blood pressure control. It is also recom-
mended not to interrupt the physical exercise programs, as
blood pressure returns to pre-training values within a few
months after the cessation of the exercise.
Aspects related to the certification for physical activities
and contraindications for sports activities in hypertensive
children and adolescents
Several scientific studies confirm that the level of phys-
ical activity is inversely proportional to mortality from
cardiovascular causes both in men and women. This
consideration holds true for hypertensive subjects as
well, in whom the absence of physical activity increase
the risk of cardiovascular diseases. It is well known that
blood pressure control during physical activity is a com-
plex process, involving increase in stroke volume and
heart rate, changes in the peripheral vascular resistances
and altered sympathetic tone. All these adaptations, al-
ways depending on one another, are related both to the
type of physical exercise and to its intensity and dur-
ation. They are also affected by gender, with more
marked changes in males compared to females, but also
by the proportion between lean mass and fat mass. Fur-
thermore it is necessary to distinguish physical exercise
in two main types: dynamic and isometric (or static).
The first type of exercise causes an increase in cardiac
output associated with rapid increases in heart rate and
systolic blood pressure (with slight decrease in diastolic
blood pressure), but also with significant reductions in
peripheral vascular resistance. Recordings have been re-
ported hat show systolic blood pressure values up to
250 mmHg during treadmill exercise stress test in young
healthy males [109]. The second type, isometric or static
exercise induces a sudden increase in both systolic and
diastolic blood pressure, a modest increase in heart rate
with an unchanged or slightly reduced stroke volume,
but no reduction in peripheral vascular resistance. In
young male weightlifters extremely high values of
systolic blood pressure up to 300–400 mmHg have been
recorded by direct intra-arterial measurements [110].
Figure 3 shows the changes and interactions between
the different parameters during static and dynamic exer-
cise [111]. From this preamble it emerges that it is ne-
cessary that young hypertensives are stimulated to
practice the kind of sports activity that is appropriate for
their individual cardiovascular condition. In 2010 the
American Academy of Pediatrics Council on Sports
Medicine and Fitness released new recommendations for
the participation in sports activities by children and ado-
lescents who have systemic hypertension [112]. In case
of high-normal blood pressure lifestyle changes should
always be encouraged (reduction of overweight and of
dietary sodium intake), avoiding the use/abuse of illegal
substances or at least those inducing an increase in
blood pressure (hormones, ephedrine, tobacco or alco-
hol) and limiting the consumption of energy or caffeine
containing drinks. At this blood pressure level there are
no particular restrictions to the type of sports activity,
but a check of blood pressure values, at least twice a
year, should be recommended. In case of stage 1 hyper-
tension, besides following the recommendations that
count for high-normal blood pressure, an accurate as-
sessment should be added aiming at excluding the pres-
ence of organ damage and, in selected cases, medical
treatment may be initiated that may not have any
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negative effect on the performance (beta-blockers and
diuretics should be avoided; diuretics are considered
“doping”). In stage 2 hypertension, even in the absence
of organ damage, it is not recommended to practice
sports that are mainly isometric and at high intensity,
such as weight lifting and push-ups, as they cause sud-
den steep increases in blood pressure. As holds for stage
1 hypertension, also in this case, pharmacological treat-
ment should be taken into consideration in an adequate
manner. Children with high-normal blood pressure, with
stage 1 hypertension without organ damage or with
pharmacologically controlled stage 2 hypertension can
participate in sports at the agonistic level. The ex-
planatory Table 10 (extracted from a document of the
“Comitato Organizzativo Cardiologico per l’Idoneità allo
Sport” [113]) reports a list of sporting activities charac-
terized by mainly pressure-related cardiocirculatory in-
volvement. This does not mean that hypertensive
children cannot occasionally practice these disciplines in
a recreational way. However, it is advisable that the
pediatrician knows that these sports are not suitable for
subjects with hypertension, not only in view of the certi-
fication for practicing non-agonistic sports, but also to
avoid that children are introduced in a certain discipline
Fig. 3 Cardiovascular response to physical exercise according to type of exercise. a Response to dynamic exercise with progressively increasing
workload up to maximal oxygen consumption. b Response to dynamic exercise (handgrip at 30 % of the maximal voluntary contraction). VO2
(ml/min/kg): oxygen consumption; HR (bpm): Heart Rate; SV (ml/beat): Stroke Volume; ABP (mmHg): systolic, diastolic and mean blood pressure;
TPR (PRU): Total Peripheral Resistance (expressed in Peripheral Resistance Unit) http://content.onlinejacc.org/data/Journals/JAC/23038/02015.pdf
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that afterwards they will not be able to perform in an ag-
onistic manner.
In Italy, unlike what happens in the United States, in
order to engage in any non-agonistic sports activity a
medical certification is requested, that involves civil and
penal responsibilities of the certifying doctor and that is
regulated by specific decrees, in particular by the most
recent changes described in the so-called Balduzzi de-
cree [114]. For obtaining this certification in healthy, or
apparently healthy children, as defined in generic terms,
blood pressure measurement and at least one electrocar-
diogram at rest should be performed (as explicitly speci-
fied in the wording on the certificate to be signed
afterwards by the physician). In the case of children and
adolescents suffering from hypertension, both primary
and secondary, it is necessary to pay more attention,
both considering the cardiovascular stress that this state
may involve, and considering the importance of imple-
menting the lifestyle changes, that should always repre-
sent the first, non-pharmacological, step that may be
useful in maintaining blood pressure values within the
normal range. In special cases (e.g., obese patient losing
weight) it is possible to certify suitability for moderate
non-agonistic sports, with a frequency of maximum 2–3
h a week in order to attain improvement in lifestyle
without at the same time weighing negatively on the car-
diovascular and osteoarticular apparatus. On the other
hand, for participation in agonistic sports activities, chil-
dren have to be referred to Sports Medicine Specialists,
who are qualified to decide what examinations should be
performed in order to obtain certification of suitability
for the specific sport and who finally sign the certificate.
Simple carbohydrates, fructose, uric acid and
hypertension
In this section we will deal with the relationship between
blood pressure, simple carbohydrates (fructose in par-
ticular) and uric acid in pediatric age. As the metabo-
lisms of these compounds are strongly interconnected, it
is not easy to distinguish the specific role of each of
them. Furthermore, they are also associated with param-
eters that characterize the metabolic syndrome, such as
hypertriglyceridemia, low levels of HDL-cholesterol,
hyperinsulinemia, type 2 diabetes mellitus, fatty liver, in
addition to their role in the development and progres-
sion of renal disease.
For the sake of clarity each compound is taken into
consideration separately.
Simple carbohydrates This term comprehends both the
monosaccharides glucose and fructose and the disac-
charide sucrose, all used in the food industry, in home-
made preparations or directly by the consumer and
which are also the sugars naturally contained in honey,
syrups, juices or fruit concentrates. One molecule of glu-
cose bound to one of fructose by a glycosidic linkage
form one molecule of sucrose, the common table sugar.
In 2000 the dietary consumption of simple carbohy-
drates in the Unites States was found to amount to
72.6 kg/person/year and it has been calculated that
about 40 % of this total was accounted for by sweetened
beverages [115]. This consumption, involving children to
a large extent, introduces a considerable caloric amount
and may be a decisive contributing factor to the current
epidemics of overweight [116], considering the fact that
calories originating from liquids do not tend to cause a
sense of satiety, whereas those in solid foods normally
do [117, 118]. In these cases we are talking about an
additional caloric intake up to about 200–300 Kcal a
day. The relationship between overweight and hyperten-
sion in pediatric age is well-known and has been widely
discussed in our previous article [119]. Furthermore it
has been shown that sugar consumption is positively
correlated with salt intake, both in adults and in children
[120, 121], and this could represent an additional mech-
anism favoring elevated blood pressure values.
Fructose Fructose is the sugar that can be found in fruit,
but in the present-day diet, the amount of fructose actu-
ally deriving from fruit is quite modest. An important
proportion of the intake of fructose derives from su-
crose, while another major source of fructose is repre-
sented by high fructose corn syrup (HFCS). This is an
Table 10 Sporting activities with mainly pressure-related
cardiocirculatory involvement, characterized by increased-to-
maximal heart rate, mean-to-increased peripheral resistances
and a non-maximal cardiac output
Mountaineering, Climbing
Athletics: speed, jumps, leaps, heptathlon, decathlon
Bobsledding, Luge
Weight lifting, Bodybuidling
Speed cycling, Mountain bike downhill, BMX
Artistic gymnastics
Synchronized swimming
Motorcycling (Motocross, Enduro, Trial)
Water skiing
Skiing: slalom, giant slalom, super G, downhill, alpine, snowboard,
carving, grass skiing.
Surfing
Tug-of-war
N.B. The following activities can be carried out occasionally and in a recreative
manner also by hypertensive children or adolescents. However, it is advisable
that the Pediatrician does not stimulate them to practice these sports
permanently; moreover, the children would not obtain the medical certificate
required for these activities to be performed as competitive sports
Comitato Organizzativo Cardiologico per l’Idoneità allo Sport ANCE, ANMCO,
FMSI, SIC, SIC SPORT [113]
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industrially produced syrup derived from corn starch, in-
troduced in the seventies, which contains 55-60 % of
fructose and is obtained by isomerization of glucose.
These syrups are frequently used in the food industry
for the production of various prepackaged foods that do
not necessarily have a sweet taste, like crackers or
ketchup, but are actually mainly employed in the pro-
duction of sweetened beverages. Finally, currently fruc-
tose is also being used in several sweeteners. A moderate
fructose intake, especially when deriving from fruit con-
sumption, is well tolerated. What does cause quite a lot
of concern, even though not yet shared by the public
opinion, is an excessive fructose load as the human body
does not envisage any system to regulate its metabolism.
Fructose can be internalized by all types of cells, but the
mechanisms of intracellular transport of this carbohy-
drate are most efficient in the liver and kidneys, and so
these two organs are mainly involved in its metabolism.
Unlike what happens with glucose, the intracellular use
of fructose does not depend on any control system that
considers the energetic state of the cell. As a conse-
quence, abundant amounts of fructose induce an uncon-
trolled cascade synthesis of fatty acids, whereas
equivalent amounts of glucose would not cause such ef-
fects [122]. Furthermore, when entering the cell fructose
is phosphorylated by an ATP-dependent fructokinase.
The presence of an excess amount of fructose causes an
increased ATP consumption, that cannot be restored
due to a relative phosphorus deficiency and in turn this
leads to progressive degradation of the high-energy com-
pounds to metabolized adenosine and finally uric acid
[123]. Moreover, it is suggested that large amounts of
fructose induce an increased activity of the enzyme fruc-
tokinase, while fructose itself may also reduce renal se-
cretion of urates [124]. The final result of these
interlinked effects is an increase in blood uric acid after
excessive consumption of fructose. The consequences of
high uric acid levels will be analyzed separately. Com-
pared to glucose, fructose appears to cause a weaker
sense of satiety due to its inability to increase insulin
and leptin secretion and to inhibit ghrelin secretion,
which are all compounds having a stimulating or inhibit-
ing effect on the satiety center in the brain [125]. Fruc-
tose is also believed to decrease basal metabolism [126].
It increases reabsorption of salt and water in the intes-
tine and in the kidneys and it has been shown that a diet
at high contents of both fructose and sodium together is
more easily associated with the development of hyper-
tension than a solely high-fructose diet [127]. Fructose
has also been reported to induce oxidative stress and to
provoke vasoconstriction by inhibiting endothelial nitric
oxide synthase [128]. In experimental animals also a
negative effect of fructose on the kidneys has been re-
vealed, inducing the development of renal hypertrophy,
glomerular hypertension, cortical vasoconstriction and
preglomerular arteriolopathy. If high fructose intake is
maintained for a long time, the renal damage, which
may be modest in the initial phases, will tend to become
chronic and may cause systemic hypertension in the
long run [129]. Although a marked increase in the risk
of gout has been demonstrated in subjects with a par-
ticularly high-fructose diet, this event is very rare in
young individuals. In spite of this, the intake of sugar-
sweetened drinks is associated with an increased risk of
hyperuricemia [130] and these observations have been
reconfirmed in a vast cohort of children and adolescents
[131], in whom an increased intake of these kind of bev-
erages corresponded with a significant increase both in
uric acid levels and in blood pressure even after correc-
tion for potential confounding factors such as BMI.
These data suggest other mechanisms, besides through
obesity, by which sugar-sweetened drinks may play a
role in the development of hypertension in the adoles-
cents. Intervention studies have shown that reduction of
carbohydrate consumption can slow the development of
the metabolic syndrome more effectively than the typical
diets that mainly reduce intake of fat. A study in Califor-
nia has demonstrated that banning soft drinks in schools
caused a reduction in their daily consumption associated
with a significant reduction of obesity in children be-
tween 6 and 11 years of age [132].
Uric acid Uric acid is produced during the breakdown
of the purine bases adenine and guanine. A diet contain-
ing food at high concentrations of these compounds can
bring about an increase in uric acid level in the blood,
especially in the presence of minor metabolic dysfunc-
tions in specific subjects. However, one should not forget
the role that excessive fructose intake can have in in-
creasing uric acid (see previous paragraph). Uric acid
can exert negative effects even at concentrations that are
lower than the ones provoking precipitation of urate
crystals in the joints. In children and adolescents it is ad-
vised to attentively examine also uric acid levels that are
at the upper limit of the normal range. The relationship
between uric acid levels and blood pressure values was
hypothesized many years ago, but lately research in this
field has become quite strong, producing numerous data
deriving from both animal and human studies, some
with interesting results in pediatric age [133]. In experi-
mental moderately hyperuricemic rats it has been ob-
served that uric acid reduces the production of nitric
oxide both at endothelial and renal level with a conse-
quent vasoconstriction in these particular areas [134]. At
vascular level uric acid stimulates smooth muscle cell
proliferation, whereas it inhibits production of new
endothelial cells. These effects, typically involved in what
is generally called endothelial dysfunction, seem to cause
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blood pressure elevations and reductions in blood flow
to the skeletal muscle, that, consequently, needs more
insulin for the uptake and disposal of excess glucose,
resulting in a clear-cut effect of insulin resistance. Fur-
thermore, such vascular alterations induce arteriolar
hyalinosis, described mainly at the level of the afferent
arterioles of mildly hyperuricemic rats, in which a fur-
ther activation of the renin-angiotensin-aldosterone sys-
tem and the onset of sodium sensitivity have been
observed, both factors that clearly contribute to the de-
velopment of hypertension. The comprehensive data de-
riving from experimental studies performed in both
animals and humans suggest the existence of two steps
in the pathogenetic mechanisms that link uric acid to
the development of hypertension [135]. Initially uric acid
activates the renin-angiotensin-aldosterone system and
suppresses nitric oxide, causing a functional increase in
the vascular resistances at systemic level. This is
followed by a second phase characterized by the devel-
opment of arteriosclerosis of the afferent glomerular ar-
terioles and the onset of sodium sensitivity, which are
both structural changes and thus hardly reversible. Uric
acid presents antioxidant properties in the extracellular
space, suggesting that it may play a protective role
against some disease conditions. Nevertheless, many
studies have shown that once uric acid enters the cells,
it starts to assume a pro-inflammatory role. Intracellular
uptake of uric acid is mediated by the transporter
URAT1. At smooth muscle cell level, the entry of uric
acid causes activation and production of growth factors
and of MCP-1 [136], which is a chemokine involved in
the formation of inflammatory infiltrates and implied in
the development of insulin resistance, because of its
additional capacity to reduce glucose uptake at the myo-
cyte level. Internalization of uric acid in adipocytes
through URAT1 has been found on the one hand to in-
duce MCP-1 production and on the other hand to re-
duce production of insulin sensitizers such as PPARγ
and adiponectin [137], thus contributing in an even
more structured manner to the development of insulin
resistance. In the kidneys, hyperuricemia has particularly
clear effects in animals with pre-existing renal disease as
it can aggravate both glomerulosclerosis and tubulointer-
stitial damage [138]. Instead, lowering uric acid by drug
treatment has been demonstrated to attenuate the pro-
gression of renal disease and hypertension [139]. Entry
of uric acid in human proximal renal tubule cells causes
apoptosis due to a mechanism that is mediated by the
activation of pro-oxidant systems [140] and this may ex-
plain, at least partly, the results of clinical studies de-
scribing how even moderately increased uric acid levels
are associated both with the onset and with the progres-
sion of chronic renal disease in different clinical settings
[141]. Non-alcoholic fatty liver disease (NAFLD) is the
result of abnormal fat accumulation in the liver and has
recently been found to be strongly related to the pres-
ence of insulin resistance, metabolic syndrome and in-
creases uric acid levels. Indeed, uric acid contributes
both to lipoprotein oxidation and to inflammation, two
important factors in the development and progression of
NAFLD. The association between NAFLD and unfavor-
able cardiovascular risk profile is increasingly supported
by scientific evidence also in the pediatric population
[142]. Preliminary data in animal models suggest that
hypouricemic therapy may improve the severity of stea-
tosis [143]. In humans the increase in uric acid has been
demonstrated to be an independent predictor of obesity,
hyperinsulinemia, diabetes, systemic hypertension, car-
diovascular and renal diseases [144]. In particular, a re-
cent meta-analysis shows that the relationship between
uric acid levels and the development of hypertension is
dose-dependent [145]. Some recent publications also
concerned subjects in the pediatric age range. Various
authors described the contemporaneous presence of
high uric acid levels and metabolic alterations [146].
Ford reported that an association between uric acid and
components of the metabolic syndrome, particular vis-
ceral obesity, is already present in children and adoles-
cents. In obese children also a significant correlation
between uric acid plasma levels, blood pressure and
HOMA index has been reported, suggesting a possible
role of uric acid in the pathogenesis of pediatric essential
hypertension mediated by the presence of insulin resist-
ance [147]. A close relationship between uric acid levels
and components of the metabolic syndrome has also
been shown in a population of Japanese adolescents
[148]. Feig was the first author to describe an association
between uricemia and the presence of hypertension in a
cohort of children and adolescents [149]. It is interesting
to emphasize that elevated urate levels were found in
subjects with primary hypertension. Jones [150] con-
firmed the relationship between uric acid and blood
pressure levels in a cohort of 104 children with primary
hypertension, undergoing 24 h ambulatory blood pres-
sure monitoring. This relationship persisted even after
correction for age, gender, race and BMI. Afterwards
other authors strengthened the evidence of this type of
association. Particularly worthy of note is a study derived
from the US registers (NHANES), demonstrating in over
6000 adolescents that those who had hypertension
showed higher uric acid levels [151]. Recently, in a cohort
of children at relatively high cardiovascular risk, a signifi-
cant correlation has been described between increasing
levels of uric acid and the grade/category of essential
hypertension (transient hypertension, prehypertension
and sustained hypertension), which persisted after correc-
tion for possible confounders, including HOMA-index
[152]. It has also been suggested that minor increases in
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uricemia in children may predict the onset of hyperten-
sion in adulthood [153]. At this moment the role of uric
acid as risk factor for the development of cardiovascular
and renal damage in very young children is being studied.
There are some preliminary reports indicating a higher
prevalence of carotid atherosclerosis in adolescents with
increased uric acid levels [142]. The relationship between
uric acid and renal tubular damage has recently been
demonstrated also in a population of hypertensive adoles-
cents with normal renal function, in whom a slight in-
crease in uric acid correlated with an increased urinary
excretion of early markers of renal injury such as NGAL
and KIM-1 [154]. Two randomized studies in hypertensive
and prehypertensive adolescents have revealed a reduction
of systolic and diastolic blood pressure values coinciding
with the administration of uric acid lowering drugs, sug-
gesting a direct causal relationship between urate and
hypertension in these subjects [155, 156]. Further studies
are needed in order to understand if uric acid lowering
pharmacological treatment should be taken into consider-
ation for hypertensive children. Recent findings support
the view that maintaining relatively low uric acid values
over time could be more effective at preventing the onset
of hypertension than lowering uric acid, to reduce blood
pressure levels once hypertension is established [157].
However, further studies are needed in order to under-
stand if uric acid is really implicated in the pathogenesis of
essential hypertension in children and adolescents.
From the foregoing the consequences in terms of both
prevention and dietary treatment of hypertension in chil-
dren are quite clear. The recommended quantities of food
intake for the Italian population (http://www.sinu.it/html/
pag/tabelle_larn_2014_rev.asp) affirm that the consump-
tion of simple carbohydrates should not exceed 15 % of
the total caloric intake, whereas the World Health
Organization (WHO) limits this quote to only 10 % and
suggests that 5 % would be ideally preferred (http://
www.who.int/mediacentre/news/releases/2015/sugar-guide-
line/en). A recent study in Italian children of 0–36 months
of age showed that as early as at six months of age only one
third of the children presented a carbohydrate intake that
was lower than 15 % of the total calories, while from
9 months on almost all children had an intake that
exceeded this value [158]. Food with a high glycemic index,
such as homogenized baby food or fruit juice with added
simple carbohydrates, contribute largely to this situation.
Fortunately some baby food companies are becoming
aware of the problem and have started to promote products
without added simple sugars. In any case it would be advis-
able to use fresh fruit instead of prepackaged products
already from weaning onwards. Even if in Italy the con-
sumption per person of simple carbohydrates seems to be
lower than that observed in the United States of America,
in order to prevent obesity, hypertension and metabolic
syndrome, it would be necessary to take measures to re-
strain the wide consumption of these foods, and beverages
in particular. Specifically, the use of fructose, that is found
in HFCS and employed as a sweetener in soft drinks, juices
or fruit drinks, should be limited. In hypertensive and pre-
hypertensive children an accurate nutritional assessment of
the consumption of simple sugars should be carried out.
The intake of these compounds should be reduced to the
amount recommended by the LARN and it would be advis-
able to eliminate sweetened beverages completely. In sub-
jects at risk of hypertension it would also be appropriate to
measure uric acid concentrations and to carefully examine
also those values that are in the high-normal range. In
those cases it would be better to avoid high-purine foods
(Table 11) as no pharmacological treatment can be pro-
posed, besides reducing the intake of fructose even more
attentively.
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